摘要
背景:注射用利培酮微球是第一个新型抗精神病药的长效制剂,它的疗效和安全性已经得到证实。但是因其注射部位为臀部深部肌肉注射,可能引起较重的疼痛刺激。目的:明确注射用利培酮微球治疗12周后注射部位疼痛情况的变化,探索注射过程及注射部位疼痛与注射剂量、注射次数的关系。方法:选择符合DSM-IV精神分裂症诊断标准的住院或门诊患者57例,年龄18～65岁,每2周注射一次利培酮微球,可根据病情调整剂量为25,37.5,50mg,同时采用100mm目测类比量表对患者注射过程疼痛和注射部位的疼痛程度进行评价,研究者应用他评量表对受试者疼痛情况进行调查,分析注射剂量、注射次数对注射过程疼痛、注射部位疼痛的影响。结果与结论:利培酮微球注射的不同剂量组间注射过程的疼痛程度差异无显著性意义(F=1.35,P>0.05),说明注射过程的疼痛与注射用利培酮微球注射剂量无关;注射部位的疼痛程度与利培酮微球的注射剂量有相关性,50mg组的疼痛程度较37.5,25mg组的注射部位的疼痛程度大,明确临床注射过程中应对高剂量利培酮微球注射患者进行重点的护理干预。
BACKGROUND：As the first long-acting atypical antipsychotics,the therapeutic effect and safety of risperidone microsphere have been proved.However,it may lead to serious pain due to the deep intramuscular injection.OBJECTIVE：To evaluate the pain levels by 12-week injection of risperidone microsphere and to explore the relationship among dose and times of injection of risperidone microsphere and pain levels.METHODS：A total of 57 patients diagnosed as schizoprenia by DSM-Ⅳ,aged 18-65 years,were selected and injected risperidone microsphere once every 2 weeks with doses of 25,37.5 and 50 mg.The pain levels were evaluated using 100 mm visual analogue scale during injection and at the injected sites.The effects of injected dose,injected frequency and injected sites on the pain were analyzed by the nurse questionnaire.RESULTS AND CONCLUSION：The pain levels among the different doses groups had no notable differences（F=1.35,P0.05）,which demonstrated that the pain had no relationship with injected dose.However,the pain level of injected sites had correlation to injected doses.The pain level of the 50 mg group was greater than that of the 37.5 and 25 mg groups.Accordingly,patients who treated by high dose of risperidone microsphere should be intervened by nurses.
出处
《中国组织工程研究与临床康复》
CAS
CSCD
北大核心
2010年第16期2937-2940,共4页
Journal of Clinical Rehabilitative Tissue Engineering Research
作者简介
王雪静，女，1978年生，河北省唐山市人，2009年河北医科大学毕业，主管护师，主要从事，临床护理。wxj19780124@sohu．com
通讯作者：李玲芝，主管护师，北京大学第六医院临床药物试验机构，北京市100191 lilingzhi80@sohu．com
